Bevacizumab, anlotinib, and etoposide for older or fragile patients with small-cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of three drugs (bevacizumab, anlotinib, and etoposide) as a first treatment for patients with metastatic small-cell lung cancer who are 65 or older, or who cannot tolerate standard intensive chemotherapy. The goal is to see if this gentler approach can effectively control the cancer while being safer for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 65 years old, or if younger, your doctor says you cannot handle strong chemotherapy (due to health problems like poor performance status or other medical conditions).
- You must have metastatic small-cell lung cancer (cancer that has spread beyond the lungs).
- You have not had any prior treatment for this stage of lung cancer (though you may have had treatment for early-stage cancer if it progressed more than 6 months ago).
- You must have at least one tumor that can be measured on a CT or MRI scan, and it must be at least 1 cm in size (or 1.5 cm for lymph nodes).
- You must be in generally adequate health, with acceptable blood counts and kidney/liver function, and no major bleeding risk.
- You cannot have certain serious conditions, such as uncontrolled high blood pressure, recent blood clots, active brain metastases needing treatment, or severe heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
This trial tests a combination of chemotherapy (etoposide), immunotherapy (benmelstobart), and a targeted drug (anlotinib) as the first treatment for older adults (ages 70–85) with extensive-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and delay growth with manageable side effects.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests combining benmelstobart (a type of immunotherapy), anlotinib (a targeted blood vessel blocker), and standard chemotherapy as the very first treatment for extensive-stage small cell lung cancer (cancer that has spread widely). It aims to see if this combination works better than current options.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) together with chest radiation to treat small cell lung cancer that hasn't spread widely and cannot be removed with surgery. The goal is to see if this combination helps people live longer and controls their cancer better.
This study tests a combination of the immunotherapy drug Adebrelimab with oral chemotherapy (etoposide) for people with small cell lung cancer who are older (65+) or have a weaker health status (ECOG score 2-3). The goal is to see if this treatment is safe and effective for those who may not be eligible for more aggressive standard treatments.
Hear when a new Small Cell Lung Cancer ( SCLC ) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.